Company PHAXIAM Therapeutics S.A. Euronext Paris

Equities

PHXM

FR0011471135

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Euronext Paris Other stock markets 11:35:26 2024-04-26 am EDT			5-day change	1st Jan Change
2.95 ^EUR	0.00%		+1.03%	-35.87%

Apr. 15	Phaxiam initiates trial in infective endocarditis	CF
Apr. 15	PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus	CI

PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.

Managers	Title	Age	Since
Thibaut du Fayet CEO	Chief Executive Officer	56	23-06-22
Eric Soyer DFI	Director of Finance/CFO	57	23-06-22
Pascal Birman CTO	Chief Tech/Sci/R&D Officer	-	23-06-22
Cindy Fevre CTO	Chief Tech/Sci/R&D Officer	-	23-06-22
Céline Breda CTO	Chief Tech/Sci/R&D Officer	54	23-06-22
Karine Charton PRN	Corporate Officer/Principal	-	23-06-22
Frédérique Vieville LAW	General Counsel	-	23-06-22
Anne-Cécile Fumey HRO	Human Resources Officer	-	23-06-22
Jérôme Bailly PRN	Corporate Officer/Principal	45	23-06-22

Members of the board	Title	Age	Since
Philippe Archinard BRD	Director/Board Member	63	23-06-22
Hilde Windels BRD	Director/Board Member	59	23-06-22
Gil Beyen BRD	Director/Board Member	62	23-06-22
Martine George BRD	Director/Board Member	76	23-06-22
Eric Jean Marie Leire BRD	Director/Board Member	66	23-06-22
Didier Hoch CHM	Chairman	68	23-06-22
Leila Nicolas BRD	Director/Board Member	-	23-06-22
Robert Sebbag BRD	Director/Board Member	73	23-06-22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,075,105	5,597,574 ( 92.14 %)	250 ( 0.004115 %)	92.14 %

Name	Equities	%	Valuation
Armistice Capital LLC 2.682 %	162,912	2.682 %	524 316 €
Auriga Partners SA 1.889 %	114,752	1.889 %	369 318 €
RECORDATI 0.7095 %	43,103	0.7095 %	138 723 €
OFI Invest Asset Management SA 0.2780 %	16,886	0.2780 %	54 346 €
BVF Partners LP 0.1602 %	9,734	0.1602 %	31 328 €
OP Asset Management Ltd. 0.1236 %	7,506	0.1236 %	24 157 €
Generali Asset Management SGR SpA 0.1152 %	7,000	0.1152 %	22 529 €
Lyxor International Asset Management SAS 0.0854 %	5,190	0.0854 %	16 703 €
Ecofi Investissements SA 0.0609 %	3,700	0.0609 %	11 908 €
Friedland Gestion SAS 0.0556 %	3,375	0.0556 %	10 862 €

Name	Equities	%	Valuation
Asset Dedication LLC 0.000000 %	0	0.000000 %	- €

Name	Equities	%	Valuation
PHAXIAM THERAPEUTICS S.A. 0.00%	250	0.00%	805 $

PHAXIAM Therapeutics SA

60, avenue Rockefeller Bâtiment Bioserra

69008, Lyon

http://www.phaxiam.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.95 EUR

Average target price

6.85 EUR

Spread / Average Target

+132.20%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs